Treatment with Tocilizumab was initiated in 349 patients (9%) with severe evolution, of which 103 (29.5%) with diabetes mellitus selected on the basis of severity criteria: sudden desaturation, increased CRP, ferritin, D-dimers, LDH, and interleukin 6 values (Figure 2). This evidence concerns the gene CRP and diabetes mellitus.